BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 28092474)

  • 1. Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).
    Simões-Pires CA; Bertrand P; Cuendet M
    Expert Opin Ther Pat; 2017 Mar; 27(3):229-236. PubMed ID: 28092474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
    Qin HT; Li HQ; Liu F
    Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.
    Thaler F
    Pharm Pat Anal; 2012 Mar; 1(1):75-90. PubMed ID: 24236715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
    De Vreese R; D'hooghe M
    Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
    He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
    Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
    Smil DV; Manku S; Chantigny YA; Leit S; Wahhab A; Yan TP; Fournel M; Maroun C; Li Z; Lemieux AM; Nicolescu A; Rahil J; Lefebvre S; Panetta A; Besterman JM; Déziel R
    Bioorg Med Chem Lett; 2009 Feb; 19(3):688-92. PubMed ID: 19111466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
    Tashima T; Murata H; Kodama H
    Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.
    Zhang Y; Feng J; Liu C; Fang H; Xu W
    Bioorg Med Chem; 2011 Aug; 19(15):4437-44. PubMed ID: 21733698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present).
    Zhao C; Dong H; Xu Q; Zhang Y
    Expert Opin Ther Pat; 2020 Apr; 30(4):263-274. PubMed ID: 32008402
    [No Abstract]   [Full Text] [Related]  

  • 11. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity.
    Liu F; Liu C; Chai Q; Zhao C; Meng H; Xue X; Yao TP; Zhang Y
    J Med Chem; 2023 Jul; 66(14):10080-10091. PubMed ID: 37463038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
    Wang J; Su M; Li T; Gao A; Yang W; Sheng L; Zang Y; Li J; Liu H
    Eur J Med Chem; 2017 Mar; 128():293-299. PubMed ID: 28213282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
    Rosik L; Niegisch G; Fischer U; Jung M; Schulz WA; Hoffmann MJ
    Cancer Biol Ther; 2014 Jun; 15(6):742-57. PubMed ID: 24618845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
    Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
    Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
    Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
    J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and therapeutic impact of HDAC6-selective inhibitors.
    Dallavalle S; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects.
    Vishwakarma S; Iyer LR; Muley M; Singh PK; Shastry A; Saxena A; Kulathingal J; Vijaykanth G; Raghul J; Rajesh N; Rathinasamy S; Kachhadia V; Kilambi N; Rajgopal S; Balasubramanian G; Narayanan S
    Int Immunopharmacol; 2013 May; 16(1):72-8. PubMed ID: 23541634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Inhibitors of Histone Deacetylase 10 (HDAC-10).
    Pojani E; Barlocco D
    Curr Med Chem; 2022; 29(13):2306-2321. PubMed ID: 34468295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.